[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507394":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":57,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Mito-MES","EXPERIMENTAL","MitoQ pills 20 mg orally daily taken during the study and initiated within 3 days post exposure.",[13],"Drug: Mitoquinone\u002Fmitoquinol mesylate",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Placebo pills orally daily taken during the study and initiated within 3 days post exposure.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Mitoquinone\u002Fmitoquinol mesylate","Mitochondrial antioxidant",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Placebo pills",[15],[32],{"name":33,"affiliation":5,"role":34},"Theodoros Kelesidis, MD, PHD, Msc","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","214-648-3486","Theodoros.Kelesidis@UTSouthwestern.edu",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Dallas","Texas","75219","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-96.80667,32.78306,{"lat":52,"lon":51},[55],{"name":56,"role":37,"phone":38,"phoneExt":26,"email":39},"Theodoros Kelesidis, MD, PhD, Msc",{"type":34,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Theodoros Kelesidis","Associate Professor of Medicine","100507394","phase-2-mitoquinonemitoquinol-mesylate-as-oral-and-safe-postexposure-prophylaxis-for-covid-19-100507394",false,"NCT05886816","Mitoquinone\u002FMitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19","Inclusion Criteria:\n\nAge 18-65 years old Asymptomatic (no symptoms of viral infection) on study entry High risk exposure without use of masks to confirmed case of COVID-19 Members in a household one of which is a confirmed case of COVID-19 Negative baseline SARS-COV-2 diagnostic test\n\nExclusion Criteria:\n\n* Women with variations in physiological functions due to hormones that may effect immune function and (transgender, pregnant, breastfeeding)\n* Specific significant clinical diseases \\[cardiovascular disease (such as coronary artery\u002Fvascular disease), heart disease (such as congestive heart failure, cardiomyopathy, atrial fibrillation), lung disease (such as chronic obstructive pulmonary disease, asthma, bronchiectasis, pulmonary fibrosis, pleural effusions), kidney disease (glomerular filtration rate or GFR less than 60 ml\u002Fmin\u002F1.73 m2), liver disease (such as cirrhosis, hepatitis), major immunosuppression (such as history of transplantation, uncontrolled HIV infection, cancer on active chemotherapy\\] based on history. Participants with well controlled HIV (CD4 count \\> 500 cells\u002Fmm\\^3 and HIV viral load \\\u003C 50 copies\u002Fml) and people with remote history of cancer not on active treatment will be allowed to participate.\n* History of known gastrointestinal disease (such as gastroparesis) that may predispose patients to nausea\n* History of auto-immune diseases\n* Chronic viral hepatitis\n* Use of systemic immunomodulatory medications (e.g. steroids) within 4 weeks of enrollment\n* Any participant who has received any investigational drug within 30 days of dosing\n* History of underlying cardiac arrhythmia\n* History of severe recent cardiac or pulmonary event\n* A history of a hypersensitivity reaction to any components of the study drug or structurally similar compounds including Coenzyme Q10 and idebenone\n* Unable to swallow tablets\n* Use of any investigational products within 4 weeks of enrollment\n* Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements.\n* Eligible for other FDA approved treatment for post-exposure prophylaxis against SARS-CoV-2\n* Use of Coenzyme Q10 or Vitamin E \\\u003C 120 days from enrollment",true,"ALL","18 Years","65 Years",{"count":71,"type":72},112,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone\u002Fmitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection.",[78,79],"SARS-CoV Infection","COVID-19",[78,79,81],"Post-exposure prophylaxis","2026-03-12",{"date":84,"type":85},"2026-03-16","ACTUAL",{"date":87,"type":85},"2024-03-01",{"date":89,"type":72},"2026-07-31",{"name":5,"class":6},1]